Ibrance heirs, Gilead's Tubulis data and more at #ASCO26

endpts.com·May 22, 2026

The recent ASCO abstracts revealed significant developments, particularly in the VEGF bispecific category and Merck and Kelun-Biotech's TROP2 ADC, sac-TMT, among other findings.

The most valuable insight for you is the emerging competition in the VEGF bispecific space, particularly with Merck and Kelun-Biotech's TROP2 ADC, sac-TMT. This development signals potential advancements and investment opportunities in targeted cancer therapies, which could impact the biotech landscape significantly.

Want more content like this?

twixb tracks your favorite blogs and social media, filters by keywords, and delivers personalized key learnings — straight to your inbox.

Create Your Own →Explore Newsfeeds

More from Healthtech & Biotech News

Recent stories curated alongside this one.

mobihealthnews.com
Epic integrates firearm injury risk screening tool from Northwell Health
Northwell Health has integrated a firearm injury risk screening tool into Epic's electronic health record system, aimed at identifying patients at risk of firearm injuries, providing them with gun locks, and referring them to intervention services. This initiative is part of a broader effort to enhance patient safety and prevent gun violence through real-time clinical interventions.
endpts.com
Shionogi wins US approval for first pill to prevent Covid following exposure
Shionogi has received FDA approval for its oral antiviral pill designed to prevent COVID-19 in both adults and children following exposure, marking a significant advancement in COVID-19 treatment options.
fiercebiotech.com
<a href="https://www.fiercebiotech.com/biotech/asco-2026-paradigm-shift-rare-gut-cancer-looms" hreflang="en">At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms</a>
At ASCO 2026, GSK introduced velzatinib, a new tyrosine kinase inhibitor aimed at treating gastrointestinal stromal tumors (GISTs), which could potentially redefine standard care by effectively targeting both primary and secondary mutations in the c-KIT enzyme. Preliminary results showed promising tumor shrinkage rates in patients, positioning velzatinib as a potential improvement over existing treatments like Gleevec and Sutent.
statnews.com
STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more
Recent data presented at the American Society of Clinical Oncology (ASCO) meeting highlights significant advancements in cancer treatment, including the pancreatic cancer drug daraxonrasib, which improves median overall survival by 60% compared to standard chemotherapy. Additionally, the meeting showcased the growing influence of China's biotechnology sector, marking a notable shift in global drug development dynamics.
statnews.com
STAT+: A turning point for pancreatic cancer patients
Revolution Medicines is making significant strides in pancreatic cancer treatment with the early access rollout of their experimental drug, daraxonrasib, which has shown promising results at the ASCO conference. Additionally, Eli Lilly announced two deals in China and Akeso's lung cancer therapy continues to exceed expectations, marking a notable period in biotech advancements.

Browse all Healthtech & Biotech News →

Ibrance heirs, Gilead's Tubulis data and more at #ASCO26

Want more content like this?

More from Healthtech & Biotech News

Epic integrates firearm injury risk screening tool from Northwell Health

Shionogi wins US approval for first pill to prevent Covid following exposure

<a href="https://www.fiercebiotech.com/biotech/asco-2026-paradigm-shift-rare-gut-cancer-looms" hreflang="en">At ASCO 2026, a ‘paradigm shift’ for a rare gut cancer looms</a>

STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and more

STAT+: A turning point for pancreatic cancer patients